Senores Pharmaceuticals Limited has published its postal ballot notice in newspapers to seek shareholder approval for the variation in the utilisation of unutilised Initial Public Offer (IPO) proceeds amounting to ₹650.16 million. The company also seeks approval for material related party transactions (RPTs) aggregating ₹754 crore and an enhancement of limits for loans and guarantees under Sections 185 and 186 of the Companies Act, 2013. The voting process commences on July 05, 2026, and concludes on August 03, 2026.

The Board of Directors, based on the recommendation of the Audit Committee, approved the proposal to reallocate funds originally earmarked for setting up a sterile injections facility in Atlanta. The unutilised amount of ₹650.16 million will be redirected towards funding the acquisition of Abbreviated New Drug Applications (ANDAs) by subsidiary Senores Pharmaceuticals Inc. (SPI), and capital expenditure for subsidiaries Apnar Pharma Private Limited and Havix Group Inc. d/b/a Aavis Pharmaceuticals. The revised utilisation timelines extend to Q4 of FY 2028.

Shareholders will vote on eight resolutions, including five ordinary resolutions for RPTs with Havix Group Inc., Ratnatris Pharmaceuticals Private Limited, Apnar Pharma Private Limited, and transactions between fellow subsidiaries. The proposed RPTs for FY 2026-27 include transactions worth ₹337 crore with Havix Group Inc., ₹113 crore with Ratnatris Pharmaceuticals Private Limited, and ₹156 crore with Apnar Pharma Private Limited. The Audit Committee has reviewed and approved these transactions, confirming they will be conducted on an arm’s length basis.

Two special resolutions seek to enhance the existing limits for loans, guarantees, and investments. The company proposes to increase the limit under Section 185 to ₹750 crore and the limit under Section 186 to ₹750 crore, up from the previously approved ₹500 crore. These enhancements are intended to provide flexibility for future business requirements and strategic initiatives.

Postal Ballot Schedule

Proposed Reallocation of IPO Proceeds

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0RB801010/eab6cb8701b44bb0.pdf

Senores Pharmaceuticals has scheduled a group meeting with analysts and institutional investors on July 7, 2026, at its corporate office in Ahmedabad, Gujarat. The interaction is set to commence at 10:00 A.M. IST and will be conducted in physical mode. The purpose of the meeting is to engage with market participants and discuss the company's performance based on publicly available data.

The company explicitly stated that no unpublished price sensitive information (UPSI) is intended to be shared during these interactions. This disclosure ensures compliance with regulatory norms regarding fair disclosure and transparency. The meeting provides an opportunity for investors to gain direct insights from the company's management regarding its operations and financial health.

The following table outlines the schedule for the meeting:

Senores Pharmaceuticals noted that the schedule is subject to change due to unforeseen exigencies on the part of the host or the company. Participants are advised to take note of this possibility. The intimation was formally submitted to the stock exchanges pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting will be attended by company officials, including senior management, to address queries from the analyst and investor community. This engagement is part of the company's regular investor relations activities to maintain open lines of communication with the market.